Could a stronger dose of risperidone help when standard treatment fails?

NCT ID NCT00539071

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a higher dose of the long-acting injectable medication risperidone (Risperdal Consta) works better than the usual dose for people with schizophrenia or schizoaffective disorder who still have symptoms despite standard treatment. 160 participants received either 50 mg or 75-100 mg every two weeks, and their symptom changes were measured over 24 weeks. The goal was to see if the higher dose improves symptom control without causing more side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
risperidone (long-acting injectable)
What this could lead to
If successful, this could show that a higher dose of long-acting risperidone helps control symptoms better in people who haven't responded well to standard doses.
What could go wrong
This is a small Phase 4 trial with only 160 participants, so results may not apply to everyone. Higher doses may also increase side effects like drowsiness or movement problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt Psychiatric Hospital

    Nashville, Tennessee, 37212-8645, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.